Cleared Traditional

K063787 - INPLEX CF MOLECULAR TEST

K063787 is an FDA 510(k) clearance for INPLEX CF MOLECULAR TEST, manufactured by Third Wave Technologies, Inc.. The device is a Class 2 Pathology device with product code NUA cleared through the Traditional 510(k) pathway after a 448-day FDA review.

K063787 · Third Wave Technologies, Inc. · Pathology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 2008
Decision
448d
Days
Class 2
Risk

K063787 is an FDA 510(k) clearance for the INPLEX CF MOLECULAR TEST. Classified as System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection (product code NUA), Class II - Special Controls.

Submitted by Third Wave Technologies, Inc. (Madison, US). The FDA issued a Cleared decision on March 13, 2008 after a review of 448 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Pathology FDA review panel, regulated under 21 CFR 866.5900 - the FDA pathology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Pathology submissions.

View all Third Wave Technologies, Inc. devices

FDA 510(k) Submission Details - K063787

510(k) Number K063787 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 21, 2006
Decision Date March 13, 2008
Days to Decision 448 days
Submission Type Traditional
Review Panel Pathology (PA)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
370d slower than avg
Panel avg: 78d · This submission: 448d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

NUA Device Classification - Class 2, Special Controls

Product Code NUA System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5900
Definition The Cftr Gene Mutation Detection System Is A Device Used To Simultaneously Detect And Identify A Panel Of Mutations And Variants In The Cftr Gene. It Is Intended As An Aid In Confirmatory Diagnostic Testing Of Individuals With Suspected Cystic Fibrosis (cf), Carrier Identification, And Newborn Screening. This Device Is Not Intended For Stand-alone Diagnostic Purposes, Prenatal Diagnostic, Pre-implantation Or Population Screening.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Pathology devices follow this clearance model.

Regulatory Peers - NUA System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection

All 11
Devices cleared under the same product code (NUA) and FDA review panel - the closest regulatory comparables to K063787.
XTAG CYSTIC FIBROSIS 39 KIT V2, (CFTR 39 KIT V2), MODEL I027C0231, I027D0266, I027E0267
K083846 · Luminex Molecular Diagnostics, Inc. · Sep 2009
VERIGENE CFTR NUCLEIC ACID TEST AND VERIGENE CFTR POLYT NUCLEIC ACID TEST
K083294 · Nanosphere, Inc. · Jul 2009
ESENSOR CF GENOTYPING TESTM ESENSOR SYSTEM, ESENSOR CYSTIC FIBROSIS GENOTYPING TEST, ESENSOR INSTRUMENT, MODELS XT-8
K090901 · Osmetech Molecular Diagnostics · Jul 2009
CYSTIC FIBROSIS GENOTYPING ASSAY, MODEL 6L20-01
K062028 · Celera Diagnostics · Sep 2007
TAG-IT CYSTIC FIBROSIS KIT
K060627 · Tm Bioscience Corporation · Jun 2006
ESENSOR CYSTIC FIBROSIS CARRIER DETECTION SYSTEM, MODEL ESENSOR 4800
K060543 · Clinical Micro Sensors, Inc. · Mar 2006